Filipe B. Rodrigues

List of Publications by Year
in descending order

85 papers	2,187 citations	331259 21 h-index	264894 42 g-index
94 all docs	94 docs citations	94 times ranked	2880 citing authors

#	Article	IF	Citations
1	An <scp>MDS</scp> Evidenceâ€Based Review on Treatments for Huntington's Disease. Movement Disorders, 2022, 37, 25-35.	2.2	19
2	Safety and Feasibility of Research Lumbar Puncture in Huntingtonâ€™s Disease: The HDClarity Cohort and Bioresource. Journal of Huntington's Disease, 2022, 11, 59-69.	0.9	7
3	Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children. Movement Disorders, 2022, 37, 1526-1531.	2.2	9
4	Natural history and burden of Huntington's disease in the <scp>UK</scp>: A <scp>populationâ€based</scp> cohort study. European Journal of Neurology, 2022, 29, 2249-2257.	1.7	6
5	Huntingtonâ€™s Disease Clinical Trials Corner: April 2022. Journal of Huntington's Disease, 2022, 11, 105-118.	0.9	16
6	A Remote Digital Monitoring Platform to Assess Cognitive and Motor Symptoms in Huntington Disease: Cross-sectional Validation Study. Journal of Medical Internet Research, 2022, 24, e32997.	2.1	15
7	The use of wearable/portable digital sensors in Huntington's disease: A systematic review. Parkinsonism and Related Disorders, 2021, 83, 93-104.	1.1	28
8	Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntingtonâ€™s disease. Scientific Reports, 2021, 11, 3481.	1.6	12
9	Botulinum toxin type A versus anticholinergics for cervical dystonia. The Cochrane Library, 2021, 2021, CD004312.	1.5	1
10	Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease. Journal of Neurochemistry, 2021, 158, 539-553.	2.1	18
11	Growth and renal function dynamics of renal oncocytomas in patients on active surveillance. BJU International, 2021, 128, 722-727.	1.3	13
12	F05â€…Biological and clinical characteristics of gene carriers far from predicted onset in the hd-yas study: a cross-sectional analysis. , 2021, , .		0
13	Deep brain stimulation for dystonia. The Cochrane Library, 2020, 2020, CD012405.	1.5	44
14	Characterizing White Matter in Huntington's Disease. Movement Disorders Clinical Practice, 2020, 7, 52-60.	0.8	20
15	Prognostic value of phrenic nerve conduction study in amyotrophic lateral sclerosis: Systematic review and meta-analysis. Clinical Neurophysiology, 2020, 131, 106-113.	0.7	2
16	Botulinum toxin type A therapy for hemifacial spasm. The Cochrane Library, 2020, 2020, CD004899.	1.5	6
17	Botulinum toxin type A therapy for blepharospasm. The Cochrane Library, 2020, 2020, CD004900.	1.5	13
18	Botulinum toxin type A therapy for cervical dystonia. The Cochrane Library, 2020, 2020, CD003633.	1.5	23

#	Article	IF	Citations
19	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. PLoS ONE, 2020, 15, e0233820.	1.1	8
20	Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntingtonâ€™s disease. Science Translational Medicine, 2020, 12, .	5.8	64
21	Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurology, The, 2020, 19, 502-512.	4.9	122
22	Strategies to minimize placebo effects in research investigations. International Review of Neurobiology, 2020, 153, 49-70.	0.9	5
23	Huntingtonâ€™s Disease Clinical Trials Corner: April 2020. Journal of Huntington's Disease, 2020, 9, 185-197.	0.9	47
24	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820.		0
25	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820.		0
26	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820.		0
27	Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntingtonâ€™s disease. , 2020, 15, e0233820.		0
28	Huntingtonâ€™s Disease Clinical Trials Corner: June 2019. Journal of Huntington's Disease, 2019, 8, 363-371.	0.9	30
29	Cerebrospinal fluid flow dynamics in Huntington's disease evaluated by phase contrast <scp>MRI</scp>. European Journal of Neuroscience, 2019, 49, 1632-1639.	1.2	5
30	Anti-TNF Drugs for Chronic Uveitis in Adultsâ€”A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Medicine, 2019, 6, 104.	1.2	21
31	Morphine in acute coronary syndrome: systematic review and meta-analysis. BMJ Open, 2019, 9, e025232.	0.8	23
32	Managing treatment fluctuations in Parkinson disease. Neurology, 2019, 92, 597-598.	1.5	1
33	Comparison of the Huntington's Disease like 2 and Huntington's Disease Clinical Phenotypes. Movement Disorders Clinical Practice, 2019, 6, 302-311.	0.8	14
34	Huntingtonâ€™s Disease Clinical Trials Corner: January 2019. Journal of Huntington's Disease, 2019, 8, 115-125.	0.9	23
35	The risks of converting post-hoc findings into primary outcomes in subsequent trials. Annals of Translational Medicine, 2019, 7, S337-S337.	0.7	0
36	Rating Scales and Performanceâ€based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations. Movement Disorders Clinical Practice, 2018, 5, 361-372.	0.8	22

#	Article	IF	Citations
37	Efficacy and safety of intravitreal antiâ€tumour necrosis factor drugs in adults with nonâ€infectious uveitis â€“ a systematic review. Acta Ophthalmologica, 2018, 96, e665-e675.	0.6	20
38	Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Healthâ€Related Quality of Life and Caregiver Quality of Life. Movement Disorders, 2018, 33, 742-749.	2.2	23
39	Huntingtonâ€™s Disease Clinical Trials Corner: February 2018. Journal of Huntington's Disease, 2018, 7, 89-98.	0.9	56
40	Neurofilament light protein in blood predicts regional atrophy in Huntington disease. Neurology, 2018, 90, e717-e723.	1.5	65
41	Cerebrospinal fluid neurogranin and TREM2 in Huntingtonâ€™s disease. Scientific Reports, 2018, 8, 4260.	1.6	25
42	Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis. Drug Safety, 2018, 41, 77-86.	1.4	17
43	D10â€...Neurofilament light protein in blood predicts regional atrophy in huntingtonâ€™s disease. , 2018, , .		0
44	D09â€...Parallel evaluation of mutant huntingtin and neurofilament light as biomarkers for huntingtonâ€™s disease: the hd-csf study. , 2018, , .		0
45	Management of Small Renal Masses. Radiology, 2018, 289, 272-273.	3.6	1
46	Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntingtonâ€™s disease. Science Translational Medicine, 2018, 10, .	5.8	134
47	Perinatal insults and neurodevelopmental disorders may impact Huntington's disease age of diagnosis. Parkinsonism and Related Disorders, 2018, 55, 55-60.	1.1	2
48	Biofluid Biomarkers in Huntingtonâ€™s Disease. Methods in Molecular Biology, 2018, 1780, 329-396.	0.4	21
49	Huntingtonâ€™s Disease Clinical Trials Corner: August 2018. Journal of Huntington's Disease, 2018, 7, 279-286.	0.9	22
50	Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?. Parkinsonism and Related Disorders, 2018, 56, 16-19.	1.1	11
51	Physician perception versus true efficacy of tetrabenazine for Huntingtonâ€™s disease. Current Medical Research and Opinion, 2018, 34, 1537-1538.	0.9	0
52	E07â€...Cerebrospinal fluid flow dynamics in huntingtonâ€™s disease using phase contrast MRI: a pilot cross-sectional study. , 2018, , .		0
53	D08â€...Neurofilament light protein in blood as a potential biomarker of neurodegeneration in hungtingtonâ€™s disease: a retrospective cohort analysis. , 2018, , .		0
54	Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?. Movement Disorders Clinical Practice, 2017, 4, 582-585.	0.8	48

#	Article	IF	Citations
55	Opicapone for the treatment of Parkinsonâ€™s disease. Expert Opinion on Pharmacotherapy, 2017, 18, 445-453.	0.9	12
56	Placebo and nocebo responses in restless legs syndrome. Neurology, 2017, 88, 2216-2224.	1.5	46
57	Survival, Mortality, Causes and Places of Death in a European Huntington's Disease Prospective Cohort. Movement Disorders Clinical Practice, 2017, 4, 737-742.	0.8	65
58	Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. Lancet Neurology, The, 2017, 16, 601-609.	4.9	272
59	Thromboprophylaxis With Apixaban in Patients Undergoing Major Orthopedic Surgery: Meta-Analysis and Trial-Sequential Analysis. Clinical Medicine Insights Blood Disorders, 2017, 10, 1179545X1770466.	0.3	7
60	Overall Survival and Causes of Death in Neurodegenerationâ€”An Overlooked and Underreported Theme. JAMA Neurology, 2017, 74, 1379.	4.5	2
61	Intracerebral hemorrhage as a manifestation of cerebral hyperperfusion syndrome after carotid revascularization: systematic review and meta-analysis. Acta Neurochirurgica, 2017, 159, 2089-2097.	0.9	16
62	Frequency of post-stroke electroencephalographic epileptiform activity â€“ a systematic review and meta-analysis of observational studies. European Stroke Journal, 2017, 2, 361-368.	2.7	8
63	Fifteen Years of Clinical Trials inÂHuntingtonâ€™s Disease: A Very Low ClinicalÂDrug Development Success Rate. Journal of Huntington's Disease, 2017, 6, 157-163.	0.9	50
64	PO104â€...Placebo and nocebo responses in rls: a meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A39.1-A39.	0.9	0
65	Botulinum toxin type A therapy for cervical dystonia. The Cochrane Library, 2017, 12, CD003633.	1.5	92
66	Clinical Trials Corner: September 2017. Journal of Huntington's Disease, 2017, 6, 255-263.	0.9	33
67	Meta-research metrics matter: letter regarding article â€œindirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington diseaseâ€. Journal of Clinical Movement Disorders, 2017, 4, 19.	2.2	13
68	K4â€...The cost and value of a huntingtonâ€™s disease multidisciplinary team meeting. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A80.2-A80.	0.9	0
69	Botulinum toxin type B for cervical dystonia. The Cochrane Library, 2016, 2016, CD004315.	1.5	36
70	Bilateral gigantic earlobe keloids. Clinical Medicine, 2016, 16, 91.	0.8	0
71	Psychogenic non-epileptic seizures in early Huntington's disease. Practical Neurology, 2016, 16, 452-454.	0.5	4
72	Mechanical Thrombectomy and Functional Outcomes After Stroke. JAMA - Journal of the American Medical Association, 2016, 315, 1791.	3.8	1

#	Article	IF	Citations
73	Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease. Journal of Neurochemistry, 2016, 139, 22-25.	2.1	58
74	Anterior ischemic optic neuropathy and hematologic malignancy: a systematic review of case reports and case series. Canadian Journal of Ophthalmology, 2016, 51, 459-466.	0.4	1
75	Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. The Cochrane Library, 2016, 2016, CD004314.	1.5	31
76	D4â€...Prediction of huntingtonâ€™s disease phenotype by cerebrospinal fluid biomarkers of inflammation and cell death. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A35.1-A35.	0.9	0
77	Endovascular treatment versus medical care alone for ischaemic stroke: systematic review and meta-analysis. BMJ, The, 2016, 353, i1754.	3.0	157
78	Deep brain stimulation for dystonia. The Cochrane Library, 2016, , .	1.5	0
79	Extended daily dialysis versus intermittent hemodialysis for acute kidney injury: A systematic review. Journal of Critical Care, 2016, 33, 271-273.	1.0	6
80	Autosomal dominant polycystic kidney disease and coronary artery dissection or aneurysm: a systematic review. Renal Failure, 2016, 38, 493-502.	0.8	17
81	Her Aching Bones: Atypical Parathyroid Adenoma. American Journal of Medicine, 2016, 129, 260-262.	0.6	2
82	Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntingtonâ€™s Disease. PLoS ONE, 2016, 11, e0163479.	1.1	58
83	Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart, 2015, 101, 1204-1211.	1.2	106
84	170. Botulinum toxins for focal dystonias: an update of 7 Cochrane systematic reviews. Toxicon, 2015, 93, S53.	0.8	0
85	Caffeine and Neuroprotection in Parkinsonâ€™s Disease. Current Topics in Neurotoxicity, 2015, , 233-272.	0.4	1